The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Previous

Liver Fibrosis Reduced with HIV-Hep C Co-Infection

Back to News Homepage

Next

Side Effects of the Two New Hep C Drugs

European Union Approves Victrelis for Chronic Hep C

Print this page

Representing the European Union’s first approved Hepatitis C drug in a decade, Victrelis (boceprevir) can now be used in Europe to battle the most persistent strain of this prevalent liver virus.

VICTRELIS(TM) (boceprevir), First-in-Class Oral Hepatitis C Virus Protease Inhibitor, Approved in the European Union for Treatment of Chronic Hepatitis C

WHITEHOUSE STATION, N.J., Jul 18, 2011 (BUSINESS WIRE) — Merck MRK -0.64% , known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved VICTRELIS(TM)(boceprevir) for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy. Chronic hepatitis C virus (HCV) is a potentially serious viral infection of the liver that affects an estimated 4 million people in Europe.

The European Commission’s Decision grants a single marketing authorisation that is valid in the 27 countries that are members of the European Union (EU), as well as unified labeling applicable to the European Economic Area members, Iceland, Liechtenstein and Norway.

Continue reading this entire article:
http://www.marketwatch.com/story/victrelistm-boceprevir-first-in-class-oral-hepatitis-c-virus-protease-inhibitor-approved-in-the-european-union-for-treatment-of-chronic-hepatitis-c-2011-07-18?reflink=MW_news_stmp

No Comments - be the first!
Share
Share

Previous

Liver Fibrosis Reduced with HIV-Hep C Co-Infection

Back to News Homepage

Next

Side Effects of the Two New Hep C Drugs

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.